Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes

Authors:

Abstract
Combined activation of GLP-1 and CCK1 receptors has potential to synergistically augment the appetite-suppressive and glucose homeostatic actions of the individual parent peptides. In the current study, pancreatic beta-cell benefits of combined GLP-1 and CCK1 receptor upregulation were established, before characterising bioactivity and antidiabetic efficacy of an acylated dual-acting GLP-1/CCK hybrid peptide, namely [Lys12Pal]Ex-4/CCK. Both exendin-4 and CCK exhibited (p12Pal]Ex-4/CCK exhibited prominent insulinotropic actions in vitro, coupled with beneficial (p12Pal]Ex-4/CCK for 28 days in diabetic high fat fed (HFF) mice with streptozotocin (STZ)-induced compromised beta-cells, there were clear reductions (p12Pal]Ex-4/CCK for the treatment of obesity-related diabetes.
Funding Information
  • European Foundation for the Study of Diabetes
  • Department for the Economy

This publication has 51 references indexed in Scilit: